{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:46:34Z","timestamp":1791942394196,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polypharmacy is often necessary in complex, chronic, comorbid and cardiovascular patients and is a known risk factor for potential drug-drug interaction (DDI) that can cause adverse reactions (toxicity or therapeutic failure). Anti-thrombotic drugs (largely low-dose aspirin and a platelet P2Y12 receptor inhibitor) and statins are among the most co-administered drugs in cardiovascular patients. Ticagrelor is a selective antagonist of the platelet P2Y12-receptor, highly effective in inhibiting platelet aggregation and bio-transformed by the CYP3A4 and substrate of transporters, such as the breast cancer resistance protein (BCRP). Statins have different pharmacokinetic profiles; some undergo CYP3A4-mediated metabolism; rosuvastatin is primarily metabolized by the CYP2C9; and they have different affinities for drug transporters. Rhabdomyolysis is a very rare but severe adverse event, which is specific for statins which can be triggered by DDIs that increase statin\u2019s concentrations through blockade of their biotransformation and\/or elimination. Large pharmacovigilance and small observational studies reported increased rhabdomyolysis in patients treated with some statins and ticagrelor but not aspirin, clopidogrel or prasugrel. Recent studies in vitro, pharmacokinetic trials and in silico drug modelling identified and validated the BCRP inhibition by ticagrelor, as a mechanism contributing to the DDI with statins, as \u2018victim\u2019 drugs, leading to increased rhabdomyolysis. While the clinical impact of this DDI deserves further investigation, a careful evaluation should be advised when ticagrelor is co-prescribed with some statins.<\/jats:p>","DOI":"10.1007\/s10557-024-07624-7","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:02:55Z","timestamp":1727690575000},"page":"1103-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ticagrelor and Statins: Dangerous Liaisons?"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bigagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"4","key":"7624_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ehjcvp\/pvac005","volume":"8","author":"J Tamargo","year":"2022","unstructured":"Tamargo J, Kjeldsen KP, Delpon E, et al. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European society of cardiology working group on cardiovascular pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022;8(4):406\u201319. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac005.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"4","key":"7624_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/2279-042X.192461","volume":"5","author":"R Kheshti","year":"2016","unstructured":"Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257\u201363. https:\/\/doi.org\/10.4103\/2279-042X.192461.","journal-title":"J Res Pharm Pract"},{"issue":"1","key":"7624_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12877-021-02183-0","volume":"21","author":"M Sheikh-Taha","year":"2021","unstructured":"Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatr. 2021;21(1):233. https:\/\/doi.org\/10.1186\/s12877-021-02183-0.","journal-title":"BMC Geriatr"},{"key":"7624_CR4","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"353","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. https:\/\/doi.org\/10.1136\/bmj.i2868.","journal-title":"BMJ"},{"issue":"1","key":"7624_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/00185787231182569","volume":"59","author":"AK Sahoo","year":"2024","unstructured":"Sahoo AK, Singh A, Gupta D, Dhaneria S, Arunima P. Assessment of potential drug-drug Interactions (pDDIs) and their risk factors among hospitalized cardiac patients in a tertiary-care center of Central India: a retrospective record-based study. Hosp Pharm. 2024;59(1):24\u201331. https:\/\/doi.org\/10.1177\/00185787231182569.","journal-title":"Hosp Pharm"},{"issue":"1","key":"7624_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cpt.3067","volume":"115","author":"M Lehtisalo","year":"2024","unstructured":"Lehtisalo M, Tarkiainen EK, Neuvonen M, et al. Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin. Clin Pharmacol Ther. 2024;115(1):71\u20139. https:\/\/doi.org\/10.1002\/cpt.3067.","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"7624_CR7","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395. https:\/\/doi.org\/10.1161\/CIR.0000000000000456.","journal-title":"Circulation"},{"issue":"1","key":"7624_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25\u201337. https:\/\/doi.org\/10.1080\/14740338.2018.1394455.","journal-title":"Expert Opin Drug Saf"},{"key":"7624_CR9","doi-asserted-by":"publisher","unstructured":"Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and when. Curr Atheroscler Rep. 2022;24(10):791\u2013801. https:\/\/doi.org\/10.1007\/s11883-022-01054-2.","DOI":"10.1007\/s11883-022-01054-2"},{"key":"7624_CR10","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nilemdo-epar-product-information_en.pdf. Accessed 20 July 2024"},{"issue":"5","key":"7624_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clpt.2006.07.006","volume":"80","author":"S Oswald","year":"2006","unstructured":"Oswald S, Giessmann T, Luetjohann D, et al. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther. 2006;80(5):477\u201385. https:\/\/doi.org\/10.1016\/j.clpt.2006.07.006.","journal-title":"Clin Pharmacol Ther"},{"issue":"38","key":"7624_CR12","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"issue":"11","key":"7624_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"issue":"9753","key":"7624_CR14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet."},{"issue":"9","key":"7624_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-018-2482-9","volume":"74","author":"KA Nguyen","year":"2018","unstructured":"Nguyen KA, Li L, Lu D, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018;74(9):1099\u2013109. https:\/\/doi.org\/10.1007\/s00228-018-2482-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"7624_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07459-8","author":"V Roule","year":"2023","unstructured":"Roule V, Alexandre J, Lemaitre A, et al. Rhabdomyolysis with co-administration of statins and antiplatelet therapies-analysis of the WHO pharmacovigilance database. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07459-8.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"7624_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40265-018-0947-x","volume":"78","author":"D Danielak","year":"2018","unstructured":"Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the risk of rhabdomyolysis and myopathy during concomitant treatment with ticagrelor and statins. Drugs. 2018;78(11):1105\u201312. https:\/\/doi.org\/10.1007\/s40265-018-0947-x.","journal-title":"Drugs"},{"issue":"1","key":"7624_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.12997\/jla.2024.13.1.61","volume":"13","author":"R Patel","year":"2024","unstructured":"Patel R, Sharma JB, Rajput S. Statins ticagrelor and rhabdomyolysis: a coincidence or a drug interaction? J Lipid Atheroscler. 2024;13(1):61\u20138. https:\/\/doi.org\/10.12997\/jla.2024.13.1.61.","journal-title":"J Lipid Atheroscler."},{"key":"7624_CR19","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brilique-epar-product-information_en.pdf.\u00a0Accessed 20 July 2024"},{"key":"7624_CR20","unstructured":"Pokhrel B, Pellegrini MV, Levine SN. PCSK9 Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07624-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T17:05:59Z","timestamp":1735319159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07624-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7624"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07624-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"20 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not relevant for an editorial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not relevant for an editorial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not relevant for an editorial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}